Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
gptkb:public_company |
| gptkbp:CEO |
gptkb:Christian_Itin
|
| gptkbp:clinicalTrialPhase |
gptkb:FELIX_study
|
| gptkbp:collaboratesWith |
gptkb:UCL_(University_College_London)
|
| gptkbp:country |
gptkb:United_Kingdom
|
| gptkbp:focusesOn |
gptkb:CAR-T_cell_therapies
immunotherapy |
| gptkbp:foundedYear |
2014
|
| gptkbp:founder |
gptkb:Martin_Pule
|
| gptkbp:headquartersLocation |
gptkb:London
|
| https://www.w3.org/2000/01/rdf-schema#label |
Autolus Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedSince |
2018
|
| gptkbp:numberOfEmployees |
200-500
|
| gptkbp:products |
gptkb:AUTO1
gptkb:AUTO3 gptkb:AUTO4 gptkb:AUTO6 obe-cel |
| gptkbp:specializesIn |
gene-modified T cell therapies
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:AUTL
|
| gptkbp:therapeuticArea |
solid tumors
hematological malignancies |
| gptkbp:website |
https://www.autolus.com/
|
| gptkbp:bfsParent |
gptkb:Blackstone_Life_Sciences
|
| gptkbp:bfsLayer |
6
|